WARFARIN SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Warfarin Sodium patents expire, and when can generic versions of Warfarin Sodium launch?
Warfarin Sodium is a drug marketed by Amneal Pharms, Aurobindo Pharma Usa, Barr, Chartwell Rx, Invagen Pharms, Ipca Labs Ltd, Pliva, Taro, Usl Pharma, Watson Labs, and Zydus Pharms Usa. and is included in seventeen NDAs.
The generic ingredient in WARFARIN SODIUM is warfarin sodium. There are twenty-two drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the warfarin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Warfarin Sodium
A generic version of WARFARIN SODIUM was approved as warfarin sodium by BARR on March 26th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for WARFARIN SODIUM?
- What are the global sales for WARFARIN SODIUM?
- What is Average Wholesale Price for WARFARIN SODIUM?
Summary for WARFARIN SODIUM
![WARFARIN SODIUM drug patent expirations Drug patent expirations by year for WARFARIN SODIUM](/p/graph/s/t/WARFARIN_SODIUM-patent-expirations.png)
![Drug Prices for WARFARIN SODIUM](/p/graph/drug-price/WARFARIN+SODIUM.png)
See drug prices for WARFARIN SODIUM
![Drug Sales Revenue Trends for WARFARIN SODIUM](/p/graph/drug-sales-revenues/WARFARIN+SODIUM.png)
Recent Clinical Trials for WARFARIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Amgen | Early Phase 1 |
Boehringer Ingelheim | N/A |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
Pharmacology for WARFARIN SODIUM
Drug Class | Vitamin K Antagonist |
Mechanism of Action | Vitamin K Inhibitors |